Literature DB >> 20734390

The association of hormonal contraceptive use and HPV prevalence.

Morgan Marks1, Patti E Gravitt, Swati B Gupta, Kai-Li Liaw, Esther Kim, Amha Tadesse, Chailert Phongnarisorn, Virach Wootipoom, Pissamai Yuenyao, Charoen Vipupinyo, Sungwal Rugpao, Somchai Sriplienchan, David D Celentano.   

Abstract

Women diagnosed with cervical cancer report longer duration and more recent use of combined oral contraceptives (COCs). It is unclear whether COC use is associated with upstream events of human papillomavirus (HPV) infection prior to development of clinical disease. The objective of our study was to assess the association of contraceptive use on the risk for prevalent HPV infection in a cohort of long-term hormonal contraceptive (HC) users. One thousand and seventy (n = 1,070) HIV-negative women aged 20-37 from Thailand enrolled in a prospective study of the natural history of HPV. Baseline HPV genotype information, recency and duration of HC use, sexual behavior, other sexually transmitted infection (STI) information and cervical cytology and histology were assessed. At enrollment, 19.8% and 11.5% of women were infected with any HPV or any high-risk (HR)-HPV, respectively. After adjustment for age, current and past sexual risk behaviors, STI history and cytology, the use of COCs for >6 years was found to be associated with an increased risk of infection with any HPV [prevalence ratio (PR): 1.88 (1.21, 2.90)] and any HR-HPV [PR: 2.68 (1.47, 4.88)] as compared to never users. Recent, long-term COC use was associated with an increased risk for prevalent HPV infection independent of sexual behavior and cervical abnormalities. No similar association was observed for recent or long duration use of progestin-only contraceptives (i.e., depomedroxyprogesterone acetate). These data suggest that COC use may impact early upstream events in the natural history of HPV infection.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20734390     DOI: 10.1002/ijc.25628

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand.

Authors:  Morgan Marks; Patti E Gravitt; Swati B Gupta; Kai-Li Liaw; Amha Tadesse; Esther Kim; Chailert Phongnarisorn; Virach Wootipoom; Pissimai Yuenyao; Charoen Vipupinyo; Somchai Sriplienchan; David D Celentano
Journal:  J Infect Dis       Date:  2011-09-29       Impact factor: 5.226

2.  The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer.

Authors:  Klaus Friese; Bernd Kost; Aurelia Vattai; Frederik Marmé; Christina Kuhn; Sven Mahner; Christian Dannecker; Udo Jeschke; Sabine Heublein
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-18       Impact factor: 4.553

3.  Injectable and oral contraception and the incidence and progression of cervical disease in HIV-infected women in South Africa.

Authors:  Daniel Westreich; Naiomi Jamal; Jennifer S Smith; Doreen Schulze; Sophie Williams; Pam Michelow; Simon Levin; Cynthia Firnhaber
Journal:  Contraception       Date:  2014-01-07       Impact factor: 3.375

4.  Incident Detection of High-Risk Human Papillomavirus Infections in a Cohort of High-Risk Women Aged 25-65 Years.

Authors:  Rachel L Winer; James P Hughes; Qinghua Feng; Joshua E Stern; Long Fu Xi; Laura A Koutsky
Journal:  J Infect Dis       Date:  2016-03-23       Impact factor: 5.226

5.  SERMs suppresses the growth of ERα positive cervical cancer xenografts through predominant inhibition of extra-nuclear ERα expression.

Authors:  Balaji Ramachandran; Kanchan Murhekar; Shirley Sundersingh
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

6.  Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67.

Authors:  Zigui Chen; Mark Schiffman; Rolando Herrero; Rob Desalle; Kathryn Anastos; Michel Segondy; Vikrant V Sahasrabuddhe; Patti E Gravitt; Ann W Hsing; Robert D Burk
Journal:  PLoS One       Date:  2011-05-27       Impact factor: 3.240

7.  Prevalence and correlates of HPV among women attending family-planning clinics in Thailand.

Authors:  Morgan A Marks; Swati Gupta; Kai-Li Liaw; Amha Tadesse; Esther Kim; Chailert Phongnarisorn; Virach Wootipoom; Pissamai Yuenyao; Charoen Vipupinyo; Sungwal Rugpao; Somchai Sriplienchan; Patti E Gravitt; David D Celentano
Journal:  BMC Infect Dis       Date:  2015-03-27       Impact factor: 3.090

8.  Classification and evolution of human papillomavirus genome variants: Alpha-5 (HPV26, 51, 69, 82), Alpha-6 (HPV30, 53, 56, 66), Alpha-11 (HPV34, 73), Alpha-13 (HPV54) and Alpha-3 (HPV61).

Authors:  Zigui Chen; Mark Schiffman; Rolando Herrero; Rob DeSalle; Kathryn Anastos; Michel Segondy; Vikrant V Sahasrabuddhe; Patti E Gravitt; Ann W Hsing; Paul K S Chan; Robert D Burk
Journal:  Virology       Date:  2018-01-11       Impact factor: 3.616

Review 9.  Towards the eradication of HPV infection through universal specific vaccination.

Authors:  Piergiorgio Crosignani; Antonella De Stefani; Gaetano Maria Fara; Andrea M Isidori; Andrea Lenzi; Carlo Antonio Liverani; Alberto Lombardi; Francesco Saverio Mennini; Giorgio Palu'; Sergio Pecorelli; Andrea P Peracino; Carlo Signorelli; Gian Vincenzo Zuccotti
Journal:  BMC Public Health       Date:  2013-07-11       Impact factor: 3.295

10.  Evolution and taxonomic classification of alphapapillomavirus 7 complete genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70.

Authors:  Zigui Chen; Mark Schiffman; Rolando Herrero; Rob DeSalle; Kathryn Anastos; Michel Segondy; Vikrant V Sahasrabuddhe; Patti E Gravitt; Ann W Hsing; Robert D Burk
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.